BioSpace News Archive

QIAGEN N.V. announced results of operations for the second quarter and first half of 2018

Knight Therapeutics Inc., and TherapeuticsMD, Inc. today announced that they have entered into a licensing agreement that grants Knight the rights to commercialize TX-004HR and TX-001HR in Canada and Israel.

Laekna to Develop and Commercialize Two Oral Akt Inhibitors with Positive Proof-of-concept Results

Orange County Business Journal recognizes 24/7 Care At Home as one of the best places of employment in Orange County.

NuVasive, Inc. announced financial results for the quarter ended June 30, 2018.

The Plant Will be First-of-its-Kind in the U.S.

TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the launch of a $65 million underwritten public offering and a concurrent $20 million registered direct offering to a strategic investor of shares of its common stock. TherapeuticsMD also expects to grant the underwriters of the underwritten public offering a 30-day...

Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals Inc., focused on developing and commercializing drugs to treat people with serious and rare diseases, today announced the publication of results from the first-ever study demonstrating the benefits of patient-to-patient connectivity in the management of familial chylomicronemia syndrome (FCS).

On August 1, 2018 Beijing time, I-Mab Biopharma announced the appointment of Jielun Zhu as Chief Financial Officer (CFO). Mr. Zhu will report directly to Dr. Jingwu Zang, Chairman and CEO of I-Mab.

If approved by the U.S. FDA, it will be the first and only patient-controlled, procedure-free, long-acting, reversible prescription birth control product to provide a full year of protection